Glox Therapeutics are grateful to PACE for their support and recognising the groundbreaking potential of our unique technology to develop precision antibiotics. Glox Therapeutics is one of only a handful of companies to have been selected for PACE funding so far which is a true testament to the expertise of world-leading team.
About us
Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Glasgow
- Type
- Privately Held
- Founded
- 2023
Locations
-
Primary
Get directions
Glasgow, GB
Employees at GLOX Therapeutics Ltd.
-
Oliver Reuss
Executive Director / Investment Manager at Boehringer Ingelheim Venture Fund; Board of Directors at Dopavision, Perfood, Brainomix, Glox
-
Daniel Walker
Professor at the University of Strathclyde, co-founder and CSO Glox Therapeutics - Developing precision protein antibiotics
-
Charlie Begley
Senior Scientist at GLOX Therapeutics Ltd.
-
Khedidja Mosbahi
Principal Scientist at Glox Therapeutics - Developing next generation precision antibiotics
Updates
-
Glox Therapeutics are grateful to PACE for their support and recognising the groundbreaking potential of our unique technology. Glox Therapeutics is one of only a handful of companies to have been selected for PACE funding so far which is a true testament to the expertise of world-leading team. AMR poses a significant threat to human health globally and this grant will enable us to expand our team and accelerate the development of our innovative engineered bacteriocins to help combat two of the most life-threatening Gram Negative pathogens.
Congratulations to GLOX Therapeutics Ltd.! We are pleased to announce that Glox Therapeutics has joined the PACE portfolio. Glox is advancing narrow-spectrum protein antibiotics for ‘Enterobactericeae’. We look forward to supporting Glox to move their project closer to the clinic, and together bring forward new precision-antibiotics in the global pipeline to tackle AMR. ➡️Find out more about the project by visiting our Portfolio page: https://lnkd.in/ej9wHstM Medicines Discovery Catapult | Innovate UK | LifeArc #WorldAMRAwarenessWeek #WAAW24 #AMR
-
-
Congratulations to GLOX Therapeutics Ltd.! We are pleased to announce that Glox Therapeutics has joined the PACE portfolio. Glox is advancing narrow-spectrum protein antibiotics for ‘Enterobactericeae’. We look forward to supporting Glox to move their project closer to the clinic, and together bring forward new precision-antibiotics in the global pipeline to tackle AMR. ➡️Find out more about the project by visiting our Portfolio page: https://lnkd.in/ej9wHstM Medicines Discovery Catapult | Innovate UK | LifeArc #WorldAMRAwarenessWeek #WAAW24 #AMR
-
-
More work is needed to publicise the threat of AMR https://lnkd.in/eBtUMh5w
-
Excited to announce that Glox Therapeutics has been shortlisted for the @University of Glasgow Spin-out of the Year award which highlights high-performing commercial or social enterprise spin-outs from University of Glasgow research. This is recognition of the great team we have at Glox Therapeutics and the significant progress the company has made in developing novel precision antibiotics. The winner will be announced at the #UofGPeopleExcellence celebration on November 21st.
Research & Innovation Services
gla.ac.uk
-
Glox Therapeutics are recruiting Senior Scientists in our Glasgow and Oxford locations to develop precision antimicrobials targeting drug resistant pathogens.
Professor at the University of Strathclyde, co-founder and CSO Glox Therapeutics - Developing precision protein antibiotics
We are looking for Senior Scientists in Glasgow and Oxford to join the Glox team and develop targeted protein antibiotics against the most problematic drug-resistant bacterial pathogens.
-
GLOX Therapeutics Ltd. reposted this
Could not agree more, especially as Nature has already discovered many antimicrobials with these properties, such as bacteriocins, lysins/endolysins and bacteriophage. Narrow-spectrum antimicrobials need the parallel development of rapid diagnostic tests, so that acute infections can be identified and an effective antimicrobial selected for treatment.
“For decades, we’ve been obsessed with creating or discovering broad-spectrum antibiotics that kill everything,” César de la Fuente, PhD said. “Why not try to come up with specific, more targeted antibiotics that only target the pathogen that is causing the infection and not all the other things that might be good for us?” Read all here 👉 https://lnkd.in/d-3PUzBt #amr #antibioticresistance #antimicrobialresistance
New antibiotic uses novel method to target deadly drug-resistant bacteria, study says | CNN
cnn.com